Deutsche Bank
http://www.db.com/
Deutsche Bank is a leading global investment bank with a strong and profitable private clients franchise.
The company operates through three divisions: Corporate and Investment Bank (CIB), Private Clients and Asset Management (PCAM) and Corporate Investments (CI) . The CIB division engages in the origination, sale, financing, structuring, and trading of fixed income, equity, equity-linked, convertible bond, foreign exchange, and commodities products. The PCAM segment provides portfolio/fund management products, including active fund management, passive/quantitative fund management, alternative investments, and discretionary portfolio management solutions in Germany and other continental European countries.-
Merck Prices $ 6.5 Billion Debt Offering
-
Zoetis (ZTS) Success Could Trigger Animal Healthcare Spin-Off Bonanza
-
Streetinsider.com's Hot Lunchtime Reads 03/12: (NOK) (JCP) (STM) (BHP) (MRK)
-
Notable Analyst Rating Changes 02/04: (BBRY) (BRO) (WU) Upgraded; (BUD) (WMT) (VOD) Downgraded
-
StreetInsider.com Pre-Open Movers 02/04: (APKT) (RMTI) (SONS) Higher; (HLF) (BUD) (NUS) Lower (more...)
-
Notable 52-Week Highs and Lows of the Day 10/03: (SRPT) (OCN) (BKD) High; (HPQ) (DELL) (XRTX) Low
-
Q2 Kickoff: Alcoa (AA) Investors to Focus on LME Prices, Downstream Ops, and China
-
Analysts Expecting Higher Bids for Amylin (AMLN)
-
Notable Analyst Rating Changes 01/09: (OPEN) (RL) (BRCM) Upgraded; (TJX) (MRK) (AFL) Downgraded
-
Q2 Preview: Divide and Conquer May Not Be Pfizer's (PFE) Best Option; Pipeline Looks Strong
-
Merck (MRK) Falling on Weak Guidance; Analysts Weigh In
-
Q3 Preview: Pfizer (PFE) Chugging Strong Into Earnings; M&A and Pipeline Key Focal Points (MRK, NVS)
-
Q3 Preview: Merck (MRK) Trading Strong Into Earnings, Looks to Nearly Double-Up Revs Y/Y (PFE, GSK, SNY)
-
Notable Analyst Rating Changes 05/05: S, CAb, ERTS, AMMD Upgraded; ITMN, MRK, NWSA, MYGN Downgraded
-
Deutsche Bank Maintains a 'Buy' on Merck (MRK); Raises PT
-
Notable Analyst Rating Changes 1/13: BIDU, WYN, HMA, IACI, MRK Upgraded; ZEUS, AFFX, GSK, PCU Downgraded
-
Notable Analyst Rating Changes 12/16: CNQ, SCHW, RCL, CCL, NLY, GLW, BFS, ADBE Upgraded; AYE, FE, EIX, STLD Downgraded
-
David Moenning's Daily State of the Markets: 7/21
-
Merck & Co. (MRK) Slammed On Speculation After Trial Abruptly Halted
-
Notable Analyst Rating Changes 7/9: GS, KBH, RIMM, ERTS Upgraded; KNXA, GET, MRK, VRX Downgraded
-
Morning Movers 4/21: ELX, THC, COH, PKG, HWG, USG Higher; ZION, LAB, NTRS, HBAN, BK, NYT Lower
-
Notable Analyst Rating Changes 3/13: HIBB, FWLT, HAL Upgraded; EMC, NOV, BJS, DKS Downgraded
-
Morning Movers 3/9: Schering-Plough (SGP) Higher On Merck (MRK) Merger, Stem Cell Stocks Rock On Obama Move To Lift Funding Restrictions
-
Notable Analyst Rating Changes 1/23: MRK, BBT, SIAL, JCG Upgraded; CME, PBR, AMD, MSCC Downgraded
-
Merck (MRK) volatility Elevated at 70 into lower 2009 Outlook
-
Analyst Expects Immediate $70/Share Offer for ImClone (IMCL) from Bristol-Myers Following News
-
David Moenning's Daily State of the Markets: 9/10
-
Notable Analyst Rating Changes 7/7: SU, JNPR, ENER Upgraded; MRK, TWX, DIS Downgraded
-
David Moenning's Daily State of the Markets: 1/30
-
Notable Analyst Rating Changes 1/28: CAT, MRK, K, GIS, FCX Upgraded; WAG, FUL, MTL Downgraded
